Literature DB >> 22105784

Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease.

Mehdi Namdar1, Jan Steffel, Sandra Jetzer, Christian Schmied, David Hürlimann, Giovanni G Camici, Fatih Bayrak, Danilo Ricciardi, Jayakeerthi Y Rao, Carlo de Asmundis, Gian-Battista Chierchia, Andrea Sarkozy, Thomas F Lüscher, Rolf Jenni, Firat Duru, Pedro Brugada.   

Abstract

Left ventricular hypertrophy is 1 of the most frequent cardiac manifestations associated with an unfavorable prognosis. However, many different causes of left ventricular hypertrophy exist. The aim of the present study was to assess the diagnostic value of common electrocardiographic (ECG) parameters to differentiate Fabry disease (FD), amyloidosis, and nonobstructive hypertrophic cardiomyopathy (HC) from hypertensive heart disease (HHD) and aortic stenosis (AS). In 94 patients with newly diagnosed FD (n = 17), HHD (n = 20), amyloidosis (n = 17), AS (n = 20), and HC (n = 20), common ECG parameters were analyzed and tested for their diagnostic value. A stepwise approach including the Sokolow-Lyon index, corrected QT duration, and PQ interval minus P-wave duration in lead II to overcome P-wave abnormalities was applied. A corrected QT duration <440 ms in combination with a PQ interval minus P-wave duration in lead II <40 ms was 100% sensitive and 99% specific for the diagnosis of FD, whereas a corrected QT duration >440 ms and a Sokolow-Lyon index ≤1.5 mV were found to have a sensitivity and specificity of 85% and 100%, respectively, for the diagnosis of amyloidosis and differentiation from HC, AS, and HHD. Moreover, a novel index ([PQ interval minus P-wave duration in lead II multiplied by corrected QT duration]/Sokolow-Lyon index) proved to be highly diagnostic for the differentiation of amyloidosis (area under the curve 0.92) and FD (area under the curve 0.91) by receiver operator characteristic analysis. In conclusion, a combined analysis of PQ interval minus P-wave duration in lead II, corrected QT duration, and Sokolow-Lyon index proved highly sensitive and specific in the differentiation of FD, amyloidosis, and HC compared to HHD and AS. Analysis of these easy-to-assess ECG parameters may be of substantial help in the diagnostic workup of these 5 conditions.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22105784     DOI: 10.1016/j.amjcard.2011.09.052

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques.

Authors:  Wael A Aljaroudi; Milind Y Desai; W H Wilson Tang; Dermot Phelan; Manuel D Cerqueira; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2014-04       Impact factor: 5.952

Review 2.  2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.

Authors:  Chung-Lieh Hung; Yen-Wen Wu; Chih-Chan Lin; Chih-Hung Lai; Jimmy Jyh-Ming Juang; Ting-Hsing Chao; Ling Kuo; Kuo-Tzu Sung; Chao-Yung Wang; Chun-Li Wang; Chun-Yuan Chu; Wen-Chung Yu; Charles Jia-Yin Hou
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

Review 3.  Restrictive Cardiomyopathies: The Importance of Noninvasive Cardiac Imaging Modalities in Diagnosis and Treatment-A Systematic Review.

Authors:  Aidonis Rammos; Vasileios Meladinis; Georgios Vovas; Dimitrios Patsouras
Journal:  Radiol Res Pract       Date:  2017-11-15

Review 4.  Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).

Authors:  A Yilmaz; J Bauersachs; F Bengel; R Büchel; I Kindermann; K Klingel; F Knebel; B Meder; C Morbach; E Nagel; E Schulze-Bahr; F Aus dem Siepen; N Frey
Journal:  Clin Res Cardiol       Date:  2021-01-18       Impact factor: 5.460

5.  Progression of electrocardiogram changes in an untreated fabry disease: a case report.

Authors:  Isabel Mattig; Sima Canaan-Kühl; Christoph Tillmanns; Fabian Knebel
Journal:  Eur Heart J Case Rep       Date:  2021-02-20

6.  The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage.

Authors:  João B Augusto; Nicolas Johner; Dipen Shah; Sabrina Nordin; Kristopher D Knott; Stefania Rosmini; Clement Lau; Mashael Alfarih; Rebecca Hughes; Andreas Seraphim; Ravi Vijapurapu; Anish Bhuva; Linda Lin; Natalia Ojrzyńska; Tarekegn Geberhiwot; Gabriella Captur; Uma Ramaswami; Richard P Steeds; Rebecca Kozor; Derralynn Hughes; James C Moon; Mehdi Namdar
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-06-22       Impact factor: 6.875

Review 7.  Electrocardiographic Changes and Arrhythmia in Fabry Disease.

Authors:  Mehdi Namdar
Journal:  Front Cardiovasc Med       Date:  2016-03-24

8.  Influence of the left ventricular types on QT intervals in hypertensive patients.

Authors:  Juraj Kunisek; Luka Zaputovic; Zlatko Cubranic; Leon Kunisek; Marta Zuvic Butorac; Ksenija Lukin-Eskinja; Rade Karlavaris
Journal:  Anatol J Cardiol       Date:  2014-04-02       Impact factor: 1.596

9.  An IoT-Based Computational Framework for Healthcare Monitoring in Mobile Environments.

Authors:  Higinio Mora; David Gil; Rafael Muñoz Terol; Jorge Azorín; Julian Szymanski
Journal:  Sensors (Basel)       Date:  2017-10-10       Impact factor: 3.576

10.  Electrocardiographic Characteristics and Their Correlation with Echocardiographic Alterations in Fabry Disease.

Authors:  Matthew Zada; Queenie Lo; Siddharth J Trivedi; Mehmet Harapoz; Anita C Boyd; Kerry Devine; Norman Sadick; Michel C Tchan; Liza Thomas
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.